References
- Folkman J. Tumor angiogenesis. The Molecular Basis of Cancer, J Mendelsohn, PM Howley, MA Israel. WB Saunders, New York 1995; 206–232
- Bouck N, Stellmach V, Hsu S. How tumors become angiogenic. Adv Cancer Res 1996; 68: 135–174
- Volpeti O V, Ward W F, Lingen M W. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996; 98: 671–679
- Lingen M W, Polverini P J, Bouck N. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab Invest 1996; 74: 376–483
- Bouck N. Understanding tumor angiogenesis. Contemp Oncol 1994; 4: 14–23
- Vogler W R, Berdel W E. Autologous bone marrow transplantation in acute leukemia with edelfosine purged marrow. Acute Leukemias IV (Prognostic Factors), T Buchner. Springer-Verlag, Berlin 1993; 669–674
- Munder P G, Modolell M, Bausert W. Alkyllysophospholip-ids in cancer therapy. Augmenting Agents in Cancer Therapy, EM Hersh. Raven Press, New York 1981; 44–458
- Berdel W E, Schlehe H, Fink U. Early tumor and leukemia response to alkyl-lysophospholipids in phase 1 study. Cancer 1982; 50: 2011–2015
- Vogler W R, Olson A C, Shoji M. Effect of alkyl-lysophospholipids on phosphatidylcholine biosynthesis in leukemic cell lines. The Pharmacological Effect of Lipids III, JJ Kabara, L Galena. American Oil Chemists Society (AOCS), Lauricidin 1989; 314–329
- Zheng B, Oishi K, Shoji M. Inhibition of protein kinasc C (Na-K-ATPase) and sodium pump by synthetic phospholipid analogues. Cancer Res 1990; 150: 3025–3031
- Helfman D M, Barnes K C, Kinkade JM, Jr. Phospholipid-sensitive Ca2+-dependent protein phosphorylation system in various types of leukemic cells from human patients and in human leukemic cell lines HL60 and K652. and its inhibition by alkyl-lysophospholipid. Cancer Res 1983; 43: 2955–2961
- Ades E W, Candal F J, Swerlick R A. HMEC-I: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992; 99: 683–690
- Candal F J, Bow D C, Vogler W R, Ades E W. Inhibition of induced angiogenesis by a human microvascular endothelial cell line by ET-18-OCH33. Cancer Chemother Pharmacol 1994; 34: 175–178
- Bosse D C, Parker J T, Vogler W R, Ades E W. Selective inhibition of adhesion molecule expression by edelfosine (ET-18-OCH3) on human umbilical vein or microvascular endothclium. Pathobiology 1996; 63: 109–114
- Huang S, Xie K, Bucana C D. Interleukin-10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res 1996; 2: 1969–1979
- Tolsma S S, Volpert O V, Good D J. Small peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993; 122: 497–511
- Berdel W E, Bausert W R, Weltzien H U. The influence of alkyl-lysophospholipids and lysophospholipid-activated macro-phages on the development of metastasis of 3-lewis lung carcinoma. Eur J Cancer 1980; 16: 1199–1204
- O'Reilly M, Holmgren S. L., Shing Y. Cell 1994; 79: 315–328
- Soldi R, Sanavio F, Agheta M. Platelet-activating factor (PAF) induces the early tyrosine phosphorylation of focal adhesion kinase (p125FAK) in human endothelial cells. Oncogene 1996; 13: 515–525
- Cohen R A, Gebbhardt B M, Bazan N G. A platelet-activating factor antagonist reduces corneal allograft inflamation and neovascu-larization. Curr Eye Res 1994; 13: 139–144
- Andrade S P, Vieira L B, Bakhle Y S, Piper P J. Effect of platelet-activating factor and other vasoconstrictors on a model of angiogenesis in the mouse. Int J Exp Pathol 1992; 73: 503–513
- Dobson D E, Kambe A, Block E. I-Butyryl-glycerol: a novel angiogenesis factor secreted by differentiating adipocytes. Cell 1990; 61: 223–230
- Wakamatsu K, Masaki T, Itoh F. Isolation of fatty acid amide as an angiogenic principle from bovine mesentery. Biochem Biophys Res Commun 1990; 168: 423–429